{
  "id": "mhgap#risk_safety_f3f5d165",
  "content": "of standardization for many non-pharmacological seem feasible in low-resource settings.\n57\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n3.6 Depression (DEP)\nDEP1. Are antidepressants (tricyclic antidepressants [TCAs]\nand selective serotonin reuptake inhibitors [SSRIs]) better\nthan (more effective than/as safe as) pill placebo/treatment\nas usual in adults with depressive episode/disorder?\nRecommendation (update): In adults with moderate-to-severe depression, citalopram, escitalopram,\nfluoxetine, fluvoxamine, paroxetine or sertraline (SSRIs) or amitriptyline\n(TCA) should be considered.\nStrength of recommendation: Conditional\nCertainty of evidence: Very low\nJustification cases where SSRIs are not available for adults with\ny Evidence was extracted from two meta-analyses: panic disorder.\nCao et al., 2021 (42 RCTs) (129) and Cipriani et al., y TCAs should be avoided in older adults and in\n2018 (522 RCTs) (130). people diagnosed with glaucoma, heart conditions,\ny SSRIs (namely citalopram, escitalopram, fluoxetine, prostatism or other prostate conditions, or at risk of\nfluvoxamine, paroxetine and sertraline) and TCAs these conditions.\n(namely amitriptyline) were significantly better than y Consider increased risk of bleeding associated\npill placebo in reducing depressive symptoms. with SSRIs, particularly for older people or people",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety of standardization for many non-pharmacological seem feasible in low-resource settings.\n57\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n3.6 Depression (DEP)\nDEP1. Are antidepressants (tricyclic antidepressants [TCAs]\nand selective serotonin reuptake inhibitors [SSRIs]) better\nthan (more effective than/as safe as) pill placebo/treatment\nas usual in adults with depressive episode/disorder?\nRecommendation (update): In adults with moderate-to-severe depression, citalopram, escitalopram,\nfluoxetine, fluvoxamine, paroxetine or sertraline (SSRIs) or amitriptyline\n(TCA) should be considered.\nStrength of recommendation: Conditional\nCertainty of evidence: Very low\nJustification cases where SSRIs are not available for adults with\ny Evidence was extracted from two meta-analyses: panic disorder.\nCao et al., 2021 (42 RCTs) (129) and Cipriani et al., y TCAs should be avoided in older adults and in\n2018 (522 RCTs) (130). people diagnosed with glaucoma, heart conditions,\ny SSRIs (namely citalopram, escitalopram, fluoxetine, prostatism or other prostate conditions, or at risk of\nfluvoxamine, paroxetine and sertraline) and TCAs these conditions.\n(namely amitriptyline) were significantly better than y Consider increased risk of bleeding associated\npill placebo in reducing depressive symptoms. with SSRIs, particularly for older people or people Of standardization for many non-pharmacological seem feasible in low-resource settings. 57\nmental health gap action programme (mhgap) guideline for mental, neurological and substance use disorders\n3.6 trầm cảm (dep)\ndep1..."
}